

10-2012

# Characterization of Secretory Sphingomyelinase Activity, Lipoprotein Sphingolipid Content and LDL Aggregation in *ldlr*<sup>-/-</sup> Mice Fed on a High-Fat Diet

Gergana M. Deevska

*University of Kentucky*, [g.deevska@uky.edu](mailto:g.deevska@uky.edu)

Manjula Sunkara

*University of Kentucky*, [manjula.sunkara@uky.edu](mailto:manjula.sunkara@uky.edu)

Andrew J. Morris

*University of Kentucky*, [a.j.morris@uky.edu](mailto:a.j.morris@uky.edu)

Mariana N. Nikolova - Karakashian

*University of Kentucky*, [mariana.karakashian@uky.edu](mailto:mariana.karakashian@uky.edu)

**Right click to open a feedback form in a new tab to let us know how this document benefits you.**

Follow this and additional works at: [https://uknowledge.uky.edu/physiology\\_facpub](https://uknowledge.uky.edu/physiology_facpub)

 Part of the [Cardiology Commons](#), and the [Physiology Commons](#)

## Repository Citation

Deevska, Gergana M.; Sunkara, Manjula; Morris, Andrew J.; and Nikolova -Karakashian, Mariana N., "Characterization of Secretory Sphingomyelinase Activity, Lipoprotein Sphingolipid Content and LDL Aggregation in *ldlr*<sup>-/-</sup> Mice Fed on a High-Fat Diet" (2012). *Physiology Faculty Publications*. 44.

[https://uknowledge.uky.edu/physiology\\_facpub/44](https://uknowledge.uky.edu/physiology_facpub/44)

This Article is brought to you for free and open access by the Physiology at UKnowledge. It has been accepted for inclusion in Physiology Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact [UKnowledge@lsv.uky.edu](mailto:UKnowledge@lsv.uky.edu).

---

**Characterization of Secretory Sphingomyelinase Activity, Lipoprotein Sphingolipid Content and LDL Aggregation in *ldlr*<sup>-/-</sup> Mice Fed on a High-Fat Diet**

**Notes/Citation Information**

Published in *Bioscience Reports*, v. 32, issue 5, p. 479–490.

© 2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (<http://creativecommons.org/licenses/by-nc/2.5/>) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.

**Digital Object Identifier (DOI)**

<http://dx.doi.org/10.1042/BSR20120036>



# Characterization of secretory sphingomyelinase activity, lipoprotein sphingolipid content and LDL aggregation in $Ildlr^{-/-}$ mice fed on a high-fat diet

Gergana M. DEEVSKA\*, Manjula SUNKARA†, Andrew J. MORRIS† and Mariana N. NIKOLOVA-KARAKASHIAN\*<sup>1</sup>

\*Department of Physiology, Division of Cardiovascular Medicine, University of Kentucky, A. B. Chandler Medical Center, Lexington, KY 40536, U.S.A., and †Department of Medicine, Division of Cardiovascular Medicine, University of Kentucky, A. B. Chandler Medical Center, Lexington, KY 40536, U.S.A.

## Synopsis

The propensity of LDLs (low-density lipoproteins) for aggregation and/or oxidation has been linked to their sphingolipid content, specifically the levels of SM (sphingomyelin) and ceramide. To investigate this association *in vivo*,  $Ildlr$  (LDL receptor)-null mice ( $Ildlr^{-/-}$ ) were fed on a modified (atherogenic) diet containing saturated fats and cholesterol. The diet led to significantly elevated SM content in all serum lipoproteins. In contrast, ceramide increased only in the LDL particles. MS-based analyses of the lipid acyl chain composition revealed a marked elevation in  $C_{16:0}$  fatty acid in SM and ceramide, consistent with the prevalence of palmitic acid in the modified diet. The diet also led to increased activity of the S-SMase [secretory SMase (sphingomyelinase)], a protein that is generated by ASMase (acid SMase) and acts on serum LDL. An increased macrophage secretion seemed to be responsible for the elevated S-SMase activity. ASMase-deficient mice ( $asm^{-/-}/Ildlr^{-/-}$ ) lacked S-SMase activity and were protected from diet-induced elevation in LDL ceramide. LDL from  $asm^{-/-}/Ildlr^{-/-}$  mice fed on the modified diet were less aggregated and oxidized than LDL from  $asm^{+/+}/Ildlr^{-/-}$  mice. When tested *in vitro*, the propensity for aggregation was dependent on the SM level: only LDL from animals on modified diet that have high SM content aggregated when treated with recombinant S-SMase. In conclusion, LDL-SM content and S-SMase activity are up-regulated in mice fed on an atherogenic diet. S-SMase mediates diet-induced changes in LDL ceramide content and aggregation. S-SMase effectiveness in inducing aggregation is dependent on diet-induced enrichment of LDL with SM, possibly through increased hepatic synthesis.

**Key words:** atherosclerosis, ceramide, low-density lipoprotein aggregation, sphingomyelin, secretory sphingomyelinase

Cite this article as: Deevska, G.M., Sunkara, M., Andrew J. Morris, A.J. and Nikolova-Karakashian, M.N. (2012) Characterization of secretory sphingomyelinase activity, lipoprotein sphingolipid content and LDL aggregation in  $Ildlr^{-/-}$  mice fed on a high-fat diet. *Biosci. Rep.* **32**, 479–490

## INTRODUCTION

SM (sphingomyelin) is a major lipid component of LDL (low-density lipoprotein) particles and together with phosphatidylcholine forms the polar surface of the lipoproteins. The SM found in the lipoproteins originates from the liver, where it is generated via the *de novo* pathway of sphingolipid synthesis and then incorporated into VLDL (very-low-density lipoprotein) particles for secretion in the circulation. The availability of SM

for lipoprotein formation depends on the rate-limiting step in its *de novo* synthesis, the SPT (serine-palmitoyl transferase) reaction [1,2]. SPT generates dihydrosphingosine, which is converted sequentially into dihydroceramide, ceramide and SM. S-SMase [secretory SMase (sphingomyelinase)] can convert SM in atherogenic serum lipoprotein particles back into ceramide [3,4]. The S-SMase enzyme, secreted by macrophages and endothelial cells, is an alternatively modified form of the 75 kDa protein product of the *asm* gene [encoding ASMase (acid SMase)], which also produces the lysosomal form of ASMase [5].

**Abbreviations used:** ABV, aorta and blood vessel; apoE, apolipoprotein E;  $C_6$ -NBD-Cer, 6-[N-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoylceramide;  $C_6$ -NBD-SM, 6-[N-(7-nitro-2,1,3-benzoxadiazol-4-yl) amino]hexanoylsphingosylphosphocholine; ESI, electrospray ionization; HDL, high-density lipoprotein; LDL, low-density lipoprotein;  $Ildlr$ , LDL receptor; L-SMase, lysosomal ASMase; SM, sphingomyelin; SMase, sphingomyelinase; ASMase, acid SMase; bSMase, bacterial SMase; SPT, serine-palmitoyl transferase; S-SMase, secretory SMase; TBARS, thiobarbituric acid-reactive substances; VLDL, very-low-density lipoprotein

<sup>1</sup> To whom correspondence should be addressed (email mnikolo@uky.edu).



Plasma SM levels have been shown to correlate with the incidence of diet-induced atherosclerosis in primates, inherent atherosclerosis in WHHL (Watanabe hereditary hyperlipidaemic) rabbits and coronary heart disease in humans [6–9]. LDL particles isolated from human arteriosclerotic lesions have high SM levels, implying that increases in serum SM are linked to sub-endothelial retention of atherogenic LDL particles [10]. In contrast, lowering the plasma SM content in apoE (apolipoprotein E)<sup>-/-</sup> mice through the pharmacological inhibition of SM synthesis in liver delays the development of atherosclerotic lesions by 42% without having any effect on total serum cholesterol or triacylglycerols [9,11,12]. These studies suggest that SM in lipoproteins may influence their atherogenic properties and thus the progression of atherosclerosis. It remains unclear, however, how the elevated SM in the circulation increases the risks for the development of atherosclerosis.

Several studies have shown that the rate of *de novo* synthesis and incorporation of SM in serum lipoproteins, as well as its degradation by the S-SMase is regulated [2,9,13,14]. Increased consumption of diets enriched in saturated fats and cholesterol leads to stimulation of *de novo* synthesis of sphingolipids in the liver [13]. The main saturated fat in these diets, palmitic acid, is a substrate for SPT and when provided in excess can stimulate SPT mRNA expression and activity [2,13]. These changes are paralleled by elevation in total plasma ceramide and SM content [9]; however, the effects atherogenic diet have on sphingolipid composition of the individual lipoproteins have not been studied. S-SMase activity, in turn, also seems to be regulated. It increases in response to IL-1 $\beta$  (interleukin-1 $\beta$ ) and IFN $\gamma$  (interferon  $\gamma$ ) stimulation of macrophages [14], in patients with CHF (chronic heart failure) [15] and Type 2 diabetes mellitus [16]. Notably, activation of S-SMase may be directly linked to the development of atherosclerosis because elevation of ceramide content in LDL particles has been shown to enhance the activity of secretory PLA<sub>2</sub> (phospholipase A<sub>2</sub>) [17], to promote LDL uptake in macrophages and to facilitate foam cell formation [18]. Ceramide-enriched LDL is isolated from atherosclerotic plaques [19,20] and is associated with accelerated LDL aggregation [21] and microvascular endothelial cell apoptosis [22,23]. Indeed, *in vitro* treatment of human LDL particles with bSMase (bacterial SMase), which similarly to S-SMase converts LDL-SM into ceramide, induces LDL aggregation [24] and oxidation [25]. It has been suggested that the sub-endothelial retention of LDL is facilitated by S-SMase-induced aggregation and binding of LDL to the matrix proteoglycans [26,27]. In contrast, asm ablation *in vivo* slows down the sub-endothelial lipoprotein retention and the development of lesions in apoE<sup>-/-</sup> and ldlr<sup>-/-</sup> mice [28].

Despite these indications that S-SMase is critical for aggregation of LDL particles, direct evidence for regulation of S-SMase activity during atherosclerosis and its role in LDL modification is still missing. In the present study, we used C57B16 and ldlr<sup>-/-</sup> mice that have ASMase deficiency (asm<sup>-/-</sup>) to characterize the effects an atherogenic diet has on sphingolipid content of lipoproteins and S-SMase activity and to investigate how S-SMase affects the propensity of LDL particles for aggregation.

## EXPERIMENTAL

### Materials

C<sub>6</sub>-NBD-Cer {6-[N-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoylceramide} and C<sub>6</sub>-NBD-SM {6-[N-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoylsphingosylphosphocholine} were from Molecular Probes, C<sub>17:0</sub> ceramide (*N*-heptadecanoyl-*D*-erythro-sphingosine), C<sub>17:0</sub> SM (*N*-heptadecanoyl-*D*-erythro-sphingosylphosphocholine), *N*-acetyl-C<sub>20</sub>-sphinganine and bovine brain ceramide were purchased from Avanti Polar Lipids. bSMase was from Sigma-Aldrich. Lowry total protein determination kit (Dc protein Assay) was from Bio-Rad. All other reagents were from Fisher Scientific.

### Animals and diets

A colony of ASMase-deficient mice (asm<sup>-/-</sup>) in C56B16 background was maintained in the AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International)-approved animal facility of University of Kentucky Medical Center by breeding heterozygous asm<sup>+/-</sup> mice. asm<sup>-/-</sup>/ldlr<sup>-/-</sup>, a double knockout mouse colony, was generated and maintained in our laboratory as described previously by litter mating of asm<sup>+/-</sup>/ldlr<sup>-/-</sup> animals [13]. Litter-matched asm<sup>-/-</sup>/ldlr<sup>-/-</sup> and asm<sup>-/-</sup> offspring and their respective controls – asm<sup>+/+</sup>/ldlr<sup>-/-</sup> and asm<sup>+/+</sup> were used throughout the experiments. After weaning, all mice were genotyped [29] and placed on a standard chow diet (2918, Teklad-Global; 18% protein rodent diet; Harlan-Teklad), 12 h light/12 h dark cycle in micro-isolation. Eight-week-old litter-matched mice from both genders were randomly placed on either a diet rich in saturated fats and cholesterol (modified diet, TD.88137, adjusted calorie diet, 42% from fat) (Harlan-Teklad) or continued on the standard diet for a period of 10 weeks. At the end of the diet, mice were deeply anaesthetized, blood was collected by heart puncture and the serum was obtained in serum separator tubes. Liver was dissected, flash-frozen in liquid nitrogen and kept at -80°C until further processed. All animal experimentations were included in our animal protocol, approved by IACUC (Institutional Animal Care and Use Committee) and carried out in complete agreement with the recommendations of the AVMA (American Veterinary Medical Association).

### Isolation of lipoprotein fractions

Lipoproteins were separated by sequential ultracentrifugation in Beckman Optima tabletop ultracentrifuge (Beckman Instruments) following a previously described procedure [30] with some modifications. Briefly, fresh serum was centrifuged at 540 000 g at 4°C for 3.7 h at a density of 1.019 g/ml to obtain VLDL (very-LDL), for 3.4 h at 1.063 g/ml for LDL and for 6.8 h at a density of 1.21 g/ml for HDL (high-density lipoproteins). After isolation, lipoprotein particles were dialysed overnight at 4°C against PBS using 0.5–3 ml Dialysis Cassettes (Pierce). The VLDL, LDL and HDL were stored under argon to prevent oxidation. Quality and physical properties of freshly isolated

lipoprotein fractions (10  $\mu\text{g}$  of protein per lane) were monitored by electrophoresis in 1.8% agarose gel and visualized with Coomassie Brilliant Blue staining.

### Isolation of peritoneal macrophages and *ex vivo* tissue cultures

Resident peritoneal macrophages were isolated from  $\text{asm}^{-/-}/\text{ldlr}^{-/-}$  and  $\text{asm}^{+/+}/\text{ldlr}^{-/-}$  on either modified or standard diets. Macrophages collected from three or four animals were pooled together and plated in 35 mm dishes at density ranging from  $1.8 \times 10^6$  to  $2.6 \times 10^6$  cells/dish. ABVs (aorta and blood vessels) surrounding the heart were dissected, cleared from visible debris of fat, cut longitudinally to expose the endothelial cells and washed twice with PBS. ABVs from mice in the same experimental group were cultured together in a 35 mm dish. For *ex vivo* assays of the fat tissue, a piece of epididymal fat from several animals (3–5 animals per group) was dissected, washed twice with PBS and placed together in 35 mm dish. Macrophages and *ex vivo* tissues were cultured in DMEM (Dulbecco's modified Eagle's medium), supplemented with 0.1% FBS and 100 units/ml of penicillin/streptomycin mix (Gibco Laboratories) for 5 h in a 37°C humidified incubator (5%  $\text{CO}_2$ ). Conditioned medium was collected, concentrated using 10 K Ultracell centrifugal filters (Amicon, Millipore) following the manufacturer's instructions and frozen for future use.

### SMase activity assays

S-SMase and L-SMase (lysosomal SMase) activities were measured using  $\text{C}_6$ -NBD-SM as a substrate. Serum samples from mice and concentrated conditioned medium were used as the source of S-SMase. The standardized assay contained serum (2  $\mu\text{l}$ ) or medium (10  $\mu\text{l}$ ), 20  $\mu\text{M}$  NBD-SM, 0.1 mM  $\text{ZnCl}_2$ , 0.1 M sodium acetate buffer (pH 5.0) in a final volume of 20  $\mu\text{l}$ . For L-SMase activity, 10  $\mu\text{g}$  of cell homogenates from macrophages were used as the enzyme source. Reactions were allowed to continue for 3 h at 37°C and were stopped by the addition of 0.5 ml of methanol. After further incubation at 37°C for 30 min, the samples were centrifuged at 1000 g and the generation of fluorescent product, NBD-ceramide, was monitored by reverse-phase HPLC using methanol/water/phosphoric acid (850:150:0.15, by vol.) as a mobile phase [31].

### Measurements of sphingolipid mass

#### Mass measurements of SM and Cer by TLC/HPLC

The lipids were extracted by the method of Blight and Dyer [32] modified as described previously [33] and were analysed by TLC on silica gel 60 plates (10 cm  $\times$  20 cm) using chloroform/methanol/triethylamine/2-propanol/0.25% potassium chloride (30:9:18:25:6, by volume) as the developing solvent. The regions migrating with a standard bovine brain ceramide were scraped from the plate. To quantify the mass of ceramide, the lipids were eluted from the silica with 1 ml of chloroform/methanol (1:1, v/v) followed by 1 ml of methanol.

The combined elutes were dried *in vacuo*, then 0.5–1.0 mol of internal standard, *N*-acetyl- $\text{C}_{20}$ -sphinganine, was added to the unknown ceramide sample and the ceramide mass was quantified by HPLC of the long-chain bases released after an acid hydrolysis in 0.5 M HCl in methanol at 65°C for 15 h. Free long-chain bases were analysed as described by Merrill et al. [34]. SM mass was measured by two approaches with similar results. LDLs were treated with bSMase (0.5 unit/ml) in 0.1 M Tris/HCl buffer, pH 7.4 for 2 h at 37°C to promote hydrolysis of SM to ceramide. The ceramide levels in SMase-treated and not-treated LDL were measured as described above and the SM content was calculated by subtracting ceramide mass measured in non-bSMase-treated samples from those that were treated with bSMase. Hepatic SM content was determined by TLC separation followed by measuring the  $\text{P}_i$  as described previously [13].


### Lipid analysis using tandem MS

Total lipid extracts from 0.5 mg of liver tissue, 30  $\mu\text{l}$  of serum and 50  $\mu\text{g}$  of VLDL and LDL were obtained using acidified organic solvents [35] with the addition of ceramide and SM internal standards containing a  $\text{C}_{17:0}$  fatty acid (Avanti Polar Lipids). After the lipid containing lower phase was evaporated to dryness under  $\text{N}_2$  and reconstituted in methanol, molecular species of SM and ceramide were detected by monitoring species-specific precursor product ion pairs by HPLC–ESI (electrospray ionization) tandem MS using 4000 Q-Trap hybrid linear ion trap triple-quadrupole mass spectrometer as described previously [36] with minor modifications. Recovery was determined by reference to the internal standards and quantification accomplished according to the calibration curves constructed using a set of synthetic standards for each ceramide and SM species obtained from Avanti Polar Lipids which were independently quantified by accurate mass measurements. SM containing cerotic ( $\text{C}_{26:0}$ ), lignoceric ( $\text{C}_{24:0}$ ), nervonic ( $\text{C}_{24:1}$ ), behenic ( $\text{C}_{22:0}$ ), arachidic ( $\text{C}_{20:0}$ ), stearic ( $\text{C}_{18:0}$ ), oleic ( $\text{C}_{18:1}$ ), palmitic ( $\text{C}_{16:0}$ ) and myristic ( $\text{C}_{14}$ ) acids was measured and also ceramides with lignoceric acid ( $\text{C}_{24:0}$ ), nervonic ( $\text{C}_{24:1}$ ), arachidic ( $\text{C}_{20:0}$ ), stearic ( $\text{C}_{18:0}$ ), oleic ( $\text{C}_{18:1}$ ), palmitic ( $\text{C}_{16:0}$ ) and myristic ( $\text{C}_{14:0}$ ) acids.

### TBARS (thiobarbituric acid-reactive substances) and turbidity assays

Oxidation in LDL was determined spectrophotometrically by measuring the amount of TBARS as described previously [37]. Briefly, 50  $\mu\text{g}$  of LDL was precipitated with 0.25 ml of 20% trichloroacetic acid. Then, 0.625 ml 0.2% thiobarbituric acid and 0.750 ml of 0.05 M sulfuric acid were added and the samples were boiled for 30 min. After cooling down, addition of 1 ml of *n*-butyl alcohol, vigorous vortex-mixing and phase separation at 1000 g for 5 min, the absorbance was measured in the upper phase at 530 nm.

The susceptibility of LDL to aggregation was determined as described previously with minor modifications [38]. LDL diluted with PBS (0.25 mg/ml) was continuously vortex-mixed for up to



**Figure 1 S-SMase activity in serum**

Mice of the indicated genotypes were placed on either a standard or modified diet for 10 weeks. S-SMase activity was measured using C<sub>6</sub>-NBD-SM as a substrate. **(A)** S-SMase activity in C57Bl6 mice measured by using 0.4 nmol of NBD-SM per sample. Results are shown as means  $\pm$  S.D. ( $n = 3$ ) for each mouse. **(B–D)** Michaelis–Menten kinetics of the S-SMase activity in C57Bl6 and *Ldlr*<sup>-/-</sup> mice on either standard or modified diet. The assays are carried out using serum (4–6 animals per assay) and the indicated substrate concentrations. Mean values of triplicates  $\pm$  S.D. are shown. \* $P < 0.05$  and \*\* $P < 0.01$  according to a Student's *t* test. SM/NBD-SM ratio in **(D)** was calculated by dividing the measured endogenous LDL-SM concentration (presented in Table 1) and the amount of NBD-SM in each assay.

5 min and the changes in absorbance at 680 nm monitored at the indicated times.

### Statistical analyses

After assuming equal variances across groups, the observed differences were tested statistically using Student's *t* test when two groups with one variable were compared or two-way ANOVA when the effects of the two parameters (diet and genotype) were assessed. Results are means  $\pm$  S.D. and are representative of at least two independent experiments. In the Figures, significance of main diet and genotype effect is indicated by \* and ^ symbols, while # indicates the significance of interaction effects.

## RESULTS

### Atherogenic diet increases S-SMase activity in serum

The effect atherogenic (modified) diet has on serum S-SMase activity and LDL sphingolipid content and properties was investigated using C57Bl6 and *Ldlr*<sup>-/-</sup> mice. The latter are the preferred animal model to study atherosclerosis and hypercholesterolaemia, because of their high serum LDL content and the possibility to easily isolate particles for biochemical and biophysical analyses. At the same time, however, our previous studies have shown that endogenous LDL distorts the S-SMase activity assay due to substrate competition [39]. To avoid this, S-Smase

activity was also assayed in C57Bl6 mice that have negligible endogenous LDL content.

Eight-week-old male mice (C57Bl6 and *Ldlr*<sup>-/-</sup>) were placed for 10 weeks either on standard chow diet (18% protein diet, containing 1% saturated fats and no cholesterol) or a modified (atherogenic) one (42% fat, calorie-adjusted diet, containing 13.8% saturated fats and 1.5% cholesterol). S-SMase activity was measured in serum using NBD-SM as a substrate. Significant increases in S-SMase activity were observed in C57Bl6 mice fed on the atherogenic diet, as compared with C57Bl6 on standard chow (Figure 1A). Judging by Michaelis–Menten analyses, both the  $K_m$  and  $V_{max}$  of the enzyme reaction were affected (Figure 1B). These results indicate that S-SMase activity is elevated in mice fed on a modified diet.

In the *Ldlr*<sup>-/-</sup> strain, however, diet-associated increases in S-SMase activity were only evident when high concentrations of the NBD-SM substrate were used (Figure 1C). Furthermore, the substrate-dependence curves did not follow the classical Michaelis–Menten pattern. One likely explanation is that the serum from *Ldlr*<sup>-/-</sup> mice on atherogenic diet has very high content of LDL (which carries the endogenous SM substrate of S-SMase), which competes with the exogenous NBD-SM substrate during the assay. Indeed, the calculated ratio between the endogenous SM present in each assay sample and the added NBD-SM was above 1:100 for assays done with C57Bl6 mice on either diets and remained in the 1:5–1:60 range for *Ldlr*<sup>-/-</sup> mice fed on the standard diet (Figure 1D). Owing to the diet-induced increases in LDL-SM, however, this ratio decreased to between 1:1 and 1:12 in the *Ldlr*<sup>-/-</sup> mice on modified diet and a competition between the substrates became noticeable. Increasing the exogenous substrate to 60 nmol (when the ratio again became higher than 1:100)

**Table 1 Effects of atherogenic diet on lipoprotein and liver sphingolipid levels**

ldlr<sup>-/-</sup> mice were placed on atherogenic diet for 10 weeks and sphingolipid classes were measured by TLC/HPLC. Serum from three or four animals was pooled for the isolation of lipoprotein particles. Results are means  $\pm$  S.D. ( $n = 3$ ). \* $P < 0.05$ . Cer, ceramide; DH-Cer, dihydroceramide.

Parameter	Sphingolipid	Diet ...	Sphingolipid level (nmol/ml of serum)		Diet ...	Sphingolipid level (nmol/mg of protein)	
			Standard	Modified		Standard	Modified
VLDL	SM		14.61 $\pm$ 1.35	220.10 $\pm$ 77.86*		52.19 $\pm$ 4.85	120.20 $\pm$ 42.54*
	Cer		4.91 $\pm$ 0.06	16.27 $\pm$ 2.18*		17.21 $\pm$ 0.22	8.89 $\pm$ 1.19*
	DH-Cer		1.24 $\pm$ 0.11	4.15 $\pm$ 1.17*		4.37 $\pm$ 0.38	2.26 $\pm$ 0.64*
LDL	SM		48.32 $\pm$ 1.64	227.64 $\pm$ 15.07*		59.65 $\pm$ 2.02	115.88 $\pm$ 25.03*
	Cer		2.64 $\pm$ 0.02	33.24 $\pm$ 1.71*		3.22 $\pm$ 0.02	15.04 $\pm$ 0.77*
	DH-Cer		0.68 $\pm$ 0.21	5.43 $\pm$ 1.82*		0.84 $\pm$ 0.32	2.81 $\pm$ 0.82*
HDL	SM		0.92 $\pm$ 0.64	36.41 $\pm$ 1.79*		2.29 $\pm$ 1.62	20.11 $\pm$ 0.98*
	Cer		0.45 $\pm$ 0.06	3.48 $\pm$ 1.54*		1.11 $\pm$ 0.14	1.92 $\pm$ 0.85
	DH-Cer		0.05 $\pm$ 0.05	0.47 $\pm$ 0.20*		0.14 $\pm$ 0.01	0.26 $\pm$ 0.11
LPDS	SM		0.22 $\pm$ 0.71	2.09 $\pm$ 0.20*		0.05 $\pm$ 0.01	0.06 $\pm$ 0.01
	Cer		1.90 $\pm$ 0.94	0.84 $\pm$ 0.07		0.12 $\pm$ 0.06	0.03 $\pm$ 0.01
	DH-Cer		0.01 $\pm$ 0.01	0.37 $\pm$ 0.03*		0.04 $\pm$ 0.07	0.60 $\pm$ 0.01
Liver	SM		N/A	N/A		0.50 $\pm$ 0.02	1.90 $\pm$ 0.40*
	Cer		N/A	N/A		0.64 $\pm$ 0.04	1.09 $\pm$ 0.20*
	DH-Cer		N/A	N/A		0.03 $\pm$ 0.02	0.09 $\pm$ 0.01*

overcomes these shortcomings of the assay. Together, these results show conclusively that diet enriched in saturated fats and cholesterol increases the activity of serum S-SMase in both animal models.

### Atherogenic diet is associated with parallel elevation of serum and hepatic sphingolipids


Analyses of sphingolipid content in total serum showed that, in ldlr<sup>-/-</sup> mice on standard chow diet, SM at 64.07 nmol/ml is the main serum sphingolipid. The concentrations of ceramide and dihydroceramide were 9.9 and 1.98 nmol/ml respectively. The diet caused drastic increases in the levels of serum SM to 486 nmol/ml, ceramide to 53.83 nmol/ml and dihydroceramide to 10.42 nmol/ml respectively. The elevation in all serum sphingolipids in mice fed on the atherogenic diet was paralleled by simultaneous accumulation of ceramide, dihydroceramide and SM in the liver (Table 1), suggesting that the changes in serum sphingolipid reflect increased sphingolipid synthesis in the liver [13]. Indeed, previous studies had associated atherogenic diet with stimulation of the *de novo* sphingolipid synthesis resulting from increased flux of dietary palmitate into the sphingolipid biosynthetic pathway and the induction of hepatic SPT mRNA transcription and activity [13]. In turn, SPT stimulation has been found to elevate hepatic secretion of SM and ceramide *in vitro* [2]. The results in Table 1 are consistent with these previous findings and illustrate *in vivo* the paralleled effect of atherogenic diet on hepatic and serum sphingolipids.

To delineate what role S-SMase has in regulating SM and ceramide content of LDL particles, analyses of individual serum lipoprotein classes were done. In mice on the atherogenic diet, the levels of sphingolipids associated with all three lipoprotein

types, VLDL, LDL and HDL, increased substantially (Table 1). After data were normalized to the protein amount in each lipoprotein fraction, the concentration of SM in VLDL and LDL in mice fed on the atherogenic diet remained significantly elevated, indicating that these particles became enriched in SM. Ceramide and dihydroceramide concentrations, on the other hand, increased significantly only in LDL but not VLDL.

### Diet-induced activation of S-SMase is accountable for the ceramide enrichment of LDL

The role S-SMase plays in determining the ceramide enrichment of LDL was investigated in sera from asm<sup>-/-</sup>/ldlr<sup>-/-</sup> and asm<sup>+/+</sup>/ldlr<sup>-/-</sup> mice placed on either modified or standard diet. In a previous study, we reported the generation of this novel composite knockout mouse strain, in which asm deficiency (asm<sup>-/-</sup>) was introduced into ldlr<sup>-/-</sup> background [13]. Feeding asm<sup>-/-</sup>/ldlr<sup>-/-</sup> mice and their respective controls, asm<sup>+/+</sup>/ldlr<sup>-/-</sup>, with atherogenic diet, revealed that the lack of ASMase had no effect on diet-induced hypercholesterolaemia, and mice from both genotypes exhibited similar increases in serum VLDL and LDL cholesterol and similar lipoprotein profiles [13]. The experiments shown in Figure 2(A) confirm that asm-deficient mice and wild-type control develop comparable hypercholesterolaemia when placed on atherogenic diet. The increases in LDL protein were also similar for both genotypes (results not shown). As anticipated, the asm-null mice have no detectable S-SMase activity thus confirming that S-SMase is the only SM-hydrolysing enzyme in mouse serum (Figure 2B). Mice deficient in S-SMase consequently have significantly higher LDL-SM content than their wild-type counterparts. This LDL-SM increases similarly for both genotypes



**Figure 2** Role of S-SMase in diet-induced changes in serum cholesterol levels and LDL-sphingolipid content

Mice of the indicated genotype were placed on either a standard or modified diet for 10 weeks (3–5 animals per group). Total serum (A and B) or purified LDL particles (C–E) were analysed for total cholesterol (A), S-SMase activity (B), SM, (C), ceramide (D) or the molar ratio of ceramide to SM (E). Values are means  $\pm$  S.D. ( $n=3$  animals per group). Statistical significance was analysed using two-way ANOVA followed by Bonferonni post-hoc test. The results of the Bonferonni post-hoc test with respect to the diet ( $*P < 0.05$ ,  $**P < 0.01$  and  $***P < 0.001$ ), genotype ( $^{\wedge}P < 0.01$ ), as well as the interaction effects from two-way ANOVA ( $^{\#}P < 0.05$  and  $^{\#\#}P < 0.01$ ) are shown.


when placed on an atherogenic diet (Figure 2C). In contrast, diet-induced increases in LDL-ceramide (and in the ceramide to SM ratio) are substantially attenuated in the *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* mice (Figures 2D and 2E). The statistical significance of the diet–genotype interaction effect based on two-way ANOVA is  $P=0.016$  for LDL-ceramide (Figure 2D) and  $P=0.01$  for the ceramide/SM ratio (Figure 2E) confirming that *asm* deletion eliminates diet-induced accumulation of ceramide in the LDL particles. This effect is specific for LDL since the corresponding elevation in ceramide observed in the liver is not reversed by the ASMase deletion [13]. Collectively, these results provide evidence that the activation of serum S-SMase facilitates the conversion of LDL-SM into ceramide in mice on atherogenic diet.

### SM and ceramide levels affect the oxidation and aggregation properties of LDL

To assess the physiological significance of the observed differences in SM and ceramide content, LDL particles from *asm<sup>+/+</sup>/ldlr<sup>-/-</sup>* and *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* on either standard or atherogenic diets were analysed for oxidation and aggregation as described previously [22]. When run on agarose gel (Figure 3A), LDL from *asm<sup>+/+</sup>/ldlr<sup>-/-</sup>* and *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* mice fed on the standard diet run as single bands. LDL particles from *asm<sup>+/+</sup>/ldlr<sup>-/-</sup>* mice fed on the high-fat diet exhibited different electrophoretic mobility, with some migrating very slowly (aggregated LDL) and others migrating at a higher rate and forming a secondary band (oxidized LDL) (Figure 3A). These indications

for aggregation and oxidation were less pronounced in the LDL from *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* mice. LDL oxidation and self-aggregation were further assessed by measuring the levels of TBARS and by assaying changes in turbidity. As shown in Figures 3(B) and 3(C), LDL particles from *asm<sup>+/+</sup>/ldlr<sup>-/-</sup>* mice on the modified diet exhibited higher TBARS values and marked increases in the turbidity of the LDL solution, as compared with LDL from *asm<sup>+/+</sup>/ldlr<sup>-/-</sup>* mice on a standard diet. In contrast, there was little increase in the turbidity and, in fact, a decrease in TBARS levels for LDL from *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* mice on a high-fat diet, as compared with *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* mice on a standard diet. Such a decrease is likely to reflect the higher SM content of the former. As mentioned before, SM has been shown to protect against LDL oxidation [25]. These results suggest that S-SMase activity contributes to the increased LDL oxidation and aggregation in mice on an atherogenic diet.

To further confirm that the conversion of LDL-SM into ceramide is a key factor determining LDL aggregation and/or oxidation, we incubated LDL particles from all groups with bSMase for 2 h at 37°C to hydrolyse LDL-SM to ceramide. A control group was treated with vehicle under the same conditions. The resulting increases in ceramide content correlated well with the initial SM levels in each type of LDL particles (Figure 3D). bSMase treatment had a pronounced effect on LDL electrophoretic mobility: (i) the proportion of particles that were retained at the start of the gel (indication of aggregation) was elevated and (ii) those particles that migrated into the gel had increased motility (indication of oxidation) (Figure 3E). These effects confirm that conversion of SM into ceramide increases LDL self-aggregation



**Figure 3** LDL biophysical properties and susceptibility to modifications


LDL particles were isolated by sequential ultracentrifugation from sera of *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* [labelled with (-/-)] and *asm<sup>+/+</sup>/ldlr<sup>-/-</sup>* [labelled with (+/+)] mice placed on either standard or modified diet for 10 weeks (3–5 animals per group). (A) Electrophoretic mobility of LDL particles (10  $\mu$ g of protein per lane) in 1.8% agarose gel visualized by Coomassie Brilliant Blue staining. (B) Oxidation of LDL assessed by measuring TBARS. Results are means  $\pm$  S.D. of triplicate measurements. Statistical significance was analysed by two-way ANOVA followed by Bonferonni *post-hoc* test. The results of the Bonferonni *post-hoc* test with respect to the diet ( $**P < 0.01$ ), genotype ( $^{\wedge}P < 0.01$ ) as well as the genotype/diet interaction effect from two-way ANOVA ( $^{\#\#\#}P < 0.001$ ) are shown. (C) Turbidity assay of LDL aggregation. Changes in absorbance were monitored at 680 nm at the indicated times. (D) TLC/HPLC determination of the increase in LDL ceramide content following treatment with bSMase (0.5 unit/ml). The increases in ceramide content due to bSMase treatment were analysed for statistical significance using two-way ANOVA and Bonferonni *post-hoc* test with respect to diet and genotype. The results of the Bonferonni test with respect to the diet ( $**P < 0.01$  and  $^{\#\#\#}P < 0.001$ ) and genotype ( $^{\wedge}P < 0.05$  and  $^{\wedge\wedge}P < 0.01$ ) are shown. (E) Effect of bSMase treatment on the electrophoretic properties of LDL particles (10  $\mu$ g of protein) in 1.8% agarose gel visualized by Coomassie Brilliant Blue staining. Representative results from at least three independent experiments, including three different isolations of LDL, are shown. Std, Standard; Mod, modified. (F) Quantification of the results shown in (E).

and/or oxidation. Notably, the rate of bSMase-induced self-aggregation correlates well with the initial levels of SM (Figure 3F). These results indicate that the LDL propensity for self-aggregation depends not only on the activity of S-SMase but also on the amount of SM available for hydrolysis. For these reasons, LDL particles from *asm<sup>+/+</sup>/ldlr<sup>-/-</sup>* mice on standard diet show the least susceptibility for aggregation, while those from *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* fed on a high-fat diet and consequently having highest SM levels were most susceptible to SMase-induced aggregation. Collectively, these findings suggest that, while S-SMase activity is indeed involved in LDL aggregation, unless the LDL particles have high levels of SM (such as those observed in the mice fed on an atherogenic diet), the net impact of S-SMase may be limited.

### Atherogenic diet stimulates S-SMase secretion by macrophages, but not by ABVs

Previous studies have suggested that ABVs and macrophages are the main source of S-SMase activity [14,40]. Therefore, we sought to determine whether these same cell types are responsible for the observed increase in S-SMase activity. Tissues were collected from mice on the respective diets and cultured *ex vivo* in the presence of defined growth media. After 5 h, the medium was collected, concentrated and S-SMase activity was measured. Only negligible activity was detected in the absence of  $Zn^{2+}$ , confirming that the activity measured was not due to enzymes released from dying/lysed cells.

S-SMase activity under standard diet was high for ABVs, as well as for resident peritoneal macrophages, while it was low for



**Figure 4 S-SMase and L-SMase activities in peritoneal macrophages, blood vessels and adipose tissue cultured ex vivo**

Mice were placed either on standard or modified diets for 10 weeks (3–5 animals per group). NBD-SM was used as a substrate to measure Zn<sup>2+</sup>-dependent S-SMase activity in conditioned medium or L-SMase activity in cellular lysates. Results are normalized per mg of cellular protein. Means ± S.D. are shown. \**P* < 0.05 compared with mice of same genotype on standard diet. **(A)** S-SMase activity in various tissues of *asm<sup>+/+</sup>/ldlr<sup>-/-</sup>* mice. **(B)** S-SMase activity in resident peritoneal macrophages from *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* and *asm<sup>+/+</sup>/ldlr<sup>-/-</sup>* mice. **(C)** L-SMase activity in lysates prepared from the same macrophages.

epididymal adipose tissue (Figure 4A). The atherogenic diet had seemingly no stimulatory effect on the S-SMase of ABVs and fat tissue. If anything, the activity of ABVs tended to decline. However, macrophages from mice on modified diet exhibited 2-fold higher S-SMase activity. As expected, the S-SMase-deficient mice had no detectable secretory activity associated with their macrophages on either diet (Figure 4B). This confirmed that the activity measured in our assays came solely from S-SMase. Importantly, the observed diet-induced enzyme stimulation was S-SMase-specific since the activity of the L-SMases, which is produced by the same gene, was not induced (Figure 4C). The ASMase activity in the cells actually declined, which could indicate re-direction of the intracellular trafficking of the ASMase precursor away from the lysosomes and towards the secretory pathways in macrophages of mice on the atherogenic diet. Such a possibility is supported by published studies showing that atherogenic diet interferes with the mannose 6-phosphate receptor system [41]. The latter is known to regulate the processing of the lysosomal and secretory form of ASMase [3]. It is also possible, however, that the decrease in macrophages ASMase results from diet-induced accumulation of cholesterol, which is an ASMase inhibitor [42]. Whatever the case, it is clear that high-fat diet has an impact on macrophage S-SMase activity and/or secretion.

### Effects of diet on liver and lipoprotein sphingolipid fatty acid composition

The bioactive properties of sphingolipids seem to depend on the length and saturation of the fatty acid attached to the primary

amine group in the sphingoid base [43–45]. Therefore RP-HPLC (reverse-phase HPLC)–ESI–tandem MS analysis was used to determine whether an atherogenic diet affects the levels of sphingolipids with specific fatty-acid content (Figure 5). The major fatty acids found in serum lipoprotein sphingolipids were nervonic (C<sub>24:1</sub>), lignoceric (C<sub>24:0</sub>) and palmitic acid (C<sub>16:0</sub>). The liver sphingolipids exhibited similar fatty-acid distribution, confirming previous studies [46]. The levels of all measured ceramide and SM species were elevated in mice fed on the modified diet. Importantly, the increases in C<sub>16:0</sub>-containing sphingolipids, however, were larger than those for sphingolipids with unsaturated or very-long-chain saturated fatty acids. As a result, the occurrence of sphingolipids with C<sub>16:0</sub> fatty acid in liver and lipoproteins of mice on an atherogenic diet increased, reflecting the high abundance of palmitate in the diet. It should be noted that elevated C<sub>16:0</sub> sphingolipid content has been associated with increased rate of apoptosis and fibrosis in liver [46,47]. Thus, the observed increases in the fraction of sphingolipids with C<sub>16:0</sub> fatty acid on palmitate-enriched diet could be associated with some of the pathology characteristics of cardiovascular diseases.


### Serum ceramide and SM profiles of ASMase-deficient mice

Lastly, we addressed the question whether S-SMase has any preference towards SM with a specific fatty acid length and/or saturation (Figure 6). The major ceramide species found in the serum of *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* and *asm<sup>+/+</sup>/ldlr<sup>-/-</sup>* mice on both diets were C<sub>24:1</sub> ceramide, followed by C<sub>24:0</sub> and C<sub>16:0</sub> ceramides (Figure 6A), which is similar to what is seen in the serum of healthy humans [23]. The most prominent SM species were C<sub>24:0</sub> and C<sub>16:0</sub> (Figure 6B). The ceramide/SM ratios for all species were uniformly affected by the diet for both mouse genotypes. This indicates that S-SMase has no apparent specificity for a substrate with a particular fatty acid. Some preference, however, may exist for the very long fatty-acid chains, since the genotype-related changes in C<sub>24:0</sub> species appeared to be somewhat larger than those for the C<sub>16:0</sub> species.

## DISCUSSION

In the present study, we describe how a diet rich in saturated fats and cholesterol affects the regulation of serum S-SMase activity and, consequently, LDL aggregation in mice. The results presented here indicate that S-SMase activity and the pool of its substrate in the form of LDL-SM are increased simultaneously and that these are two key factors that influence LDL aggregation. We also show that S-SMase activity is required for LDL aggregation; however, unless the LDL particles have sufficiently high SM levels (such as those observed during consumption of an atherogenic diet), the net impact of S-SMase may be limited.

SM is the second most abundant phospholipid class in LDL particles and together with phosphatidylcholine makes up the



**Figure 5** Fatty acid composition of the SM and ceramide in liver, VLDL and LDL


Acidified organic solvents were used to prepare total lipid extracts from liver homogenates, VLDL and LDL from *asm<sup>+/+</sup>/ldlr<sup>-/-</sup>* mice (three to five animals per group) fed either standard or modified diet. Ceramide and SM internal standards containing a C<sub>17:0</sub> fatty acid were added at the start to account for any losses during the extraction. Sphingolipid species containing different fatty acids were detected by monitoring species-specific precursor product ion pairs using HPLC-ESI-tandem MS and 4000 Q-Trap hybrid linear ion trap triple-quadrupole mass spectrometer. Levels of the respective dihydro species were sometimes too low for proper quantification and therefore were not included.

surface of the lipoproteins [48]. The main determinant of serum SM levels is the rate of its synthesis and secretion by the liver in the form of VLDL. This VLDL is later modified to LDL via the action of various lipases [49]. In the liver, the synthesis of SM is controlled by the rate of the SPT reaction, which is a rate-limiting step of sphingolipid biosynthesis [1]. Palmitic acid, the most abundant fatty acid in many pro-atherogenic diets is also the sole fatty acid used as a substrate of SPT. Numerous studies have reported that an increased supply of palmitate stimulates SPT activity and leads to the accumulation of dihydroceramide, ceramide, SM and other complex sphingolipids in liver, muscle and fat tissue [50]. The experiments described in the present study provide the first evidence that diet-induced changes in sphingolipid content are not limited to these tissues but are passed on to the serum lipoproteins. Elevation of serum VLDL and LDL cholesterol is the hallmark of atherosclerosis and is a well-established consequence of extended consumption of diets that are rich in saturated fats and cholesterol. Our studies provide evidence that the elevated serum cholesterol is paralleled by elevation in serum sphingolipids. In magnitude, the changes in SM synthesis seemingly surpass the stimulation of VLDL and LDL secretion, causing the production of particles that are enriched in SM.

The experiments shown in this study also reveal that LDL-SM influences the propensity of LDL for aggregation. The underlying

mechanism apparently involves two independent steps. First, diet-induced stimulation of *de novo* SM synthesis in the liver results in the secretion of LDL particles that are enriched in SM, providing excess substrate for S-SMase. Secondly, simultaneous stimulation of S-SMase activity causes the increased conversion of LDL-SM into ceramide, leading to aggregation. Previous studies from Ira Tabas's group, which first characterized S-SMase activity, have shown that recombinant bacterial SMase can hydrolyse SM in human LDL, inducing aggregation [51]. Our work builds upon these findings to further show that LDL isolated from animals deficient in S-SMase that are fed on an atherogenic diet are in fact less aggregated and oxidized than LDL from animals with a functional S-SMase. These observations are direct indications for the key role S-SMase plays in LDL aggregation and are also consistent with the previously reported decrease in diet-induced plaque formation in *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* mice [28].

The LDL susceptibility for aggregation depends on the levels of S-SMase substrated LDL-SM. In the present study, LDL from *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* animals fed on an atherogenic diet that had the highest SM content, were most susceptible to aggregation upon treatment with bSMase. In contrast, particles from *asm<sup>+/+</sup>/ldlr<sup>-/-</sup>* mice on the standard diet had the lowest SM content and aggregated the least when similarly treated. These observations suggest that LDL-SM in animals on a standard diet



**Figure 6 Ceramide and SM species in the serum of mice on atherogenic or control diet**

Total serum lipid extracts were prepared from  $asm^{-/-}/ldlr^{-/-}$  and  $asm^{+/+}/ldlr^{-/-}$  mice placed on either standard (Std) or modified (Md) diet for 10 weeks. Ceramide (A) and SM (B) species were quantified by monitoring precursor product ion pairs using HPLC–ESI/tandem MS. The ceramide/SM molar ratio was calculated in each sample (C). Means  $\pm$  S.D. are shown ( $n = 3$  animals per group). Bonferonni post-hoc test analyses comparing the effect of the diet for mice from the same genotype are shown (\* $P < 0.05$  and # $P < 0.001$ ). Std, standard diet; Md, modified diet.

is so low that even its complete conversion into ceramide is not sufficient to induce aggregation without diet-induced SM enrichment of LDL particles. In support of this notion, it has been reported that LDL particles isolated from SM synthase 2 transgenic mice aggregate more when treated with recombinant SMase than LDL from wild-type mice [52].

Another important finding of our studies is that palmitate-rich diet not only elevates SM and ceramide content but also modifies the fatty acid profile of these sphingolipids by increasing the proportion of  $C_{16:0}$  species. The bioactive properties of ceramide are known to depend on the length and saturation of the fatty acid attached to the primary amine group in the sphingoid base [43–45]. An elevated proportion of  $C_{16}$ -sphingolipids in the liver is associated with increased apoptosis, even in the absence of net accumulation of ceramide [46,47]. In our study, the atherogenic diet led to the hepatic accumulation of sphingolipid species that are potentially detrimental to cellular functions and could be involved in some of the pathologies and complications typical of atherosclerosis. Whether or not the specific increases in LDL  $C_{16:0}$  ceramide and SM affect LDL properties is not clear. However, uptake of LDL with elevated ceramide content by vascular endothelial cells has been linked to increased

apoptosis [22]; therefore the enrichment with  $C_{16:0}$  and  $C_{18:0}$  species may have indirect effects in such cases of LDL particle uptake.

In conclusion, S-SMase is emerging as a key regulator of LDL aggregation, based on direct evidence from knockout animal models of atherosclerosis presented in this work as well as in previous reports by other investigators. Importantly, the effects of S-SMase are dependent on the SM content of LDL, which is substantially increased by the atherogenic diet. Furthermore, the fatty-acid composition of sphingolipids is seemingly sensitive to changes in dietary fat that might be vital for understanding the effects saturated fatty acids have on cell functions.

#### AUTHOR CONTRIBUTION

Gergana Deevska was responsible for carrying out all the experiments described in the study except for MS. She also participated in experimental design, data interpretation and manuscript preparation. Manjula Sunkara performed the MS analysis. Andrew Morris developed the methods for lipid analyses by MS, supervised Manjula Sunkara, helped with interpretation of the results from MS and critically evaluated the paper. Mariana Nikolova-Karakashian

participated in experimental design, troubleshooting, data interpretation and preparation of the paper.

#### ACKNOWLEDGEMENTS

We thank A.A. Karakashian for critical reading and editing of the manuscript prior to submission, and two former members of the laboratory, Dr Boyanovsky and Dr Giltiy for preliminary studies with *asm<sup>-/-</sup>/ldlr<sup>-/-</sup>* mice.

#### FUNDING

This work was supported by the National Institutes of Health [grant numbers AG019223 and AG026711 (to M.N.K.) and GM50388 and P20RR021954 for LC-MS/MS analyses (to A.J.M.)].

#### REFERENCES

- Merrill, Jr, A. H., Wang, E. and Mullins, R. E. (1988) Kinetics of long-chain (sphingoid) base biosynthesis in intact LM cells: effects of varying the extracellular concentrations of serine and fatty acid precursors of this pathway. *Biochemistry* **27**, 340–345
- Merrill, Jr, A. H., Lingrell, S., Wang, E., Nikolova-Karakashian, M., Vales, T. R. and Vance, D. E. (1995) Sphingolipid biosynthesis *de novo* by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion. *J. Biol. Chem.* **270**, 13834–13841
- Tabas, I. (1999) Secretory sphingomyelinase. *Chem. Phys. Lipids* **102**, 123–130
- Oorni, K., Posio, P., Ala-Korpela, M., Jauhiainen, M. and Kovanen, P. T. (2005) Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. *Arterioscler. Thromb. Vasc. Biol.* **25**, 1678–1683
- Schissel, S. L., Jiang, X., Tweedie-Hardman, J., Jeong, T., Camejo, E. H., Najib, J., Rapp, J. H., Williams, K. J. and Tabas, I. (1998) Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. *J. Biol. Chem.* **273**, 2738–2746
- Benade, A. J., Fincham, J. E., Smuts, C. M., Tung, M. T., Chalton, D., Kruger, M., Weight, M. J., Daubitzer, A. K. and Tichelaar, H. Y. (1988) Plasma low density lipoprotein composition in relation to atherosclerosis in nutritionally defined Vervet monkeys. *Atherosclerosis* **74**, 157–168
- Chao, F. F., Blanchette-Mackie, E. J., Chen, Y. J., Dickens, B. F., Berlin, E., Amende, L. M., Skarlatos, S. I., Gamble, W., Resau, J. H., Mergner, W. T. et al. (1990) Characterization of two unique cholesterol-rich lipid particles isolated from human atherosclerotic lesions. *Am. J. Pathol.* **136**, 169–179
- Jiang, X. C., Paultre, F., Pearson, T. A., Reed, R. G., Francis, C. K., Lin, M., Berglund, L. and Tall, A. R. (2000) Plasma sphingomyelin level as a risk factor for coronary artery disease. *Arterioscler. Thromb. Vasc. Biol.* **20**, 2614–2618
- Hojjati, M. R., Li, Z., Zhou, H., Tang, S., Huan, C., Ooi, E., Lu, S. and Jiang, X. C. (2005) Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. *J. Biol. Chem.* **280**, 10284–10289
- Hara, A. and Taketomi, T. (1990) Characterization and change of phospholipids in the aorta of Watanabe heritable hyperlipidemic rabbit. *Japan. J. Exp. Med.* **60**, 311–318
- Park, T. S., Panek, R. L., Rekhter, M. D., Mueller, S. B., Rosebury, W. S., Robertson, A., Hanselman, J. C., Kindt, E., Homan, R. and Karathanasis, S. K. (2006) Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. *Atherosclerosis* **189**, 264–272
- Glaros, E. N., Kim, W. S., Quinn, C. M., Jessup, W., Rye, K. A. and Garner, B. (2008) Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. *J. Lipid Res.* **49**, 324–331
- Deevska, G. M., Rozenova, K. A., Giltiy, N. V., Chambers, M. A., White, J., Boyanovsky, B. B., Wei, J., Daugherty, A., Smart, E. J., Reid, M. B. et al. (2009) Acid sphingomyelinase deficiency prevents diet-induced hepatic triacylglycerol accumulation and hyperglycemia in mice. *J. Biol. Chem.* **284**, 8359–83568
- Marathe, S., Schissel, S. L., Yellin, M. J., Beatini, N., Mintzer, R., Williams, K. J. and Tabas, I. (1998) Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. *J. Biol. Chem.* **273**, 4081–4088
- Doehner, W., Bunck, A. C., Rauchhaus, M., von Haehling, S., Brunkhorst, F. M., Ciccoira, M., Tschope, C., Ponikowski, P., Claus, R. A. and Anker, S. D. (2007) Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. *Eur. Heart J.* **28**, 821–828
- Gorska, M., Baranczuk, E. and Dobrzyn, A. (2003) Secretory Zn<sup>2+</sup>-dependent sphingomyelinase activity in the serum of patients with type 2 diabetes is elevated. *Horm. Metab. Res.* **35**, 506–507
- Koumanov, K. S., Momchilova, A. B., Quinn, P. J. and Wolf, C. (2002) Ceramides increase the activity of the secretory phospholipase A<sub>2</sub> and alter its fatty acid specificity. *Biochem. J.* **363**, 45–51
- Morita, S. Y., Kawabe, M., Sakurai, A., Okuhira, K., Vertut-Doi, A., Nakano, M. and Handa, T. (2004) Ceramide in lipid particles enhances heparan sulfate proteoglycan and low density lipoprotein receptor-related protein-mediated uptake by macrophages. *J. Biol. Chem.* **279**, 24355–24361
- Ichi, I., Nakahara, K., Kiso, K. and Kojo, S. (2007) Effect of dietary cholesterol and high fat on ceramide concentration in rat tissues. *Nutrition* **23**, 570–574
- Schissel, S. L., Tweedie-Hardman, J., Rapp, J. H., Graham, G., Williams, K. J. and Tabas, I. (1996) Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. *J. Clin. Invest.* **98**, 1455–1464
- Walters, M. J. and Wrenn, S. P. (2008) Effect of sphingomyelinase-mediated generation of ceramide on aggregation of low-density lipoprotein. *Langmuir* **24**, 9642–9647
- Boyanovsky, B., Karakashian, A., King, K., Giltiy, N. and Nikolova-Karakashian, M. (2003) Uptake and metabolism of low density lipoproteins with elevated ceramide content by human microvascular endothelial cells: implications for the regulation of apoptosis. *J. Biol. Chem.* **278**, 26992–26999
- Ichi, I., Nakahara, K., Miyashita, Y., Hidaka, A., Kutsukake, S., Inoue, K., Maruyama, T., Miwa, Y., Harada-Shiba, M., Tsushima, M. and Kojo, S. (2006) Association of ceramides in human plasma with risk factors of atherosclerosis. *Lipids* **41**, 859–863
- Pentikainen, M. O., Lehtonen, E. M. and Kovanen, P. T. (1996) Aggregation and fusion of modified low density lipoprotein. *J. Lipid Res.* **37**, 2638–2649
- Subbaiah, P. V., Subramanian, V. S. and Wang, K. (1999) Novel physiological function of sphingomyelin in plasma. Inhibition of lipid peroxidation in low density lipoproteins. *J. Biol. Chem.* **274**, 36409–36414



- 26 Williams, K. J. and Tabas, I. (1995) The response-to-retention hypothesis of early atherogenesis. *Arterioscler. Thromb. Vasc. Biol.* **15**, 551–561
- 27 Oorni, K., Hakala, J. K., Annala, A., Ala-Korpela, M. and Kovanen, P. T. (1998) Sphingomyelinase induces aggregation and fusion, but phospholipase A<sub>2</sub> only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans. *J. Biol. Chem.* **273**, 29127–29134
- 28 Devlin, C. M., Leventhal, A. R., Kuriakose, G., Schuchman, E. H., Williams, K. J. and Tabas, I. (2008) Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. *Arterioscler. Thromb. Vasc. Biol.* **28**, 1723–1730
- 29 Yu, Z. F., Nikolova-Karakashian, M., Zhou, D., Cheng, G., Schuchman, E. H. and Mattson, M. P. (2000) Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis. *J. Mol. Neurosci.* **15**, 85–97
- 30 Tong, H., Knapp, H. R. and Van Rollins, M. (1998) A low temperature flotation method to rapidly isolate lipoproteins from plasma. *J. Lipid Res.* **39**, 1696–1704
- 31 Nikolova-Karakashian, M., Morgan, E. T., Alexander, C., Liotta, D. C. and Merrill, Jr, A. H. (1997) Bimodal regulation of ceramidase by interleukin-1 $\beta$ . Implications for the regulation of cytochrome P450 2C11. *J. Biol. Chem.* **272**, 18718–18724
- 32 Bligh, E. G. and Dyer, W. J. (1959) A rapid method of total lipid extraction and purification. *Can. J. Med. Sci.* **37**, 911–917
- 33 Williams, R. D., Wang, E. and Merrill, Jr, A. H. (1984) Enzymology of long-chain base synthesis by liver: characterization of serine palmitoyltransferase in rat liver microsomes. *Arch. Biochem. Biophys.* **228**, 282–291
- 34 Merrill, Jr, A. H., Wang, E., Mullins, R. E., Jamison, W. C., Nimkar, S. and Liotta, D. C. (1988) Quantitation of free sphingosine in liver by high-performance liquid chromatography. *Anal. Biochem.* **171**, 373–381
- 35 Pamuklar, Z., Federico, L., Liu, S., Umezu-Goto, M., Dong, A., Panchatcharam, M., Fulkerson, Z., Berdyshev, E., Natarajan, V., Fang, X. et al. (2009) Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. *J. Biol. Chem.* **284**, 7385–7394
- 36 Sullards, M. C., Allegood, J. C., Kelly, S., Wang, E., Haynes, C. A., Park, H., Chen, Y. and Merrill, Jr, A. H. (2007) Structure-specific, quantitative methods for analysis of sphingolipids by liquid chromatography-tandem mass spectrometry: 'inside-out' sphingolipidomics. *Methods Enzymol.* **432**, 83–115
- 37 Ordoas, J. M. (1998) *Lipoprotein Protocols*, Humana Press, Totowa, NJ
- 38 Guyton, J. R., Klemp, K. F. and Mims, M. P. (1991) Altered ultrastructural morphology of self-aggregated low density lipoproteins: coalescence of lipid domains forming droplets and vesicles. *J. Lipid Res.* **32**, 953–962
- 39 Sathishkumar, S., Boyanovsky, B., Karakashian, A. A., Rozenova, K., Giltaiy, N. V., Kudrimoti, M., Mohiuddin, M., Ahmed, M. M. and Nikolova-Karakashian, M. (2005) Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: implications for endothelial apoptosis. *Cancer Biol. Ther.* **4**, 979–986
- 40 Schissel, S. L., Schuchman, E. H., Williams, K. J. and Tabas, I. (1996) Zn<sup>2+</sup>-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. *J. Biol. Chem.* **271**, 18431–18436
- 41 Wu, D., Sharan, C., Yang, H., Goodwin, J. S., Zhou, L., Grabowski, G. A., Du, H. and Guo, Z. (2007) Apolipoprotein E-deficient lipoproteins induce foam cell formation by downregulation of lysosomal hydrolases in macrophages. *J. Lipid Res.* **48**, 2571–2578
- 42 Reagan, Jr, J. W., Hubbert, M. L. and Shelness, G. S. (2000) Posttranslational regulation of acid sphingomyelinase in Niemann-pick type C1 fibroblasts and free cholesterol-enriched Chinese hamster ovary cells. *J. Biol. Chem.* **275**, 38104–38110
- 43 Renert, A. F., Leprince, P., Dieu, M., Renaut, J., Raes, M., Bours, V., Chapelle, J. P., Piette, J., Merville, M. P. and Fillet, M. (2009) The proapoptotic C<sub>16</sub>-ceramide-dependent pathway requires the death-promoting factor Btf in colon adenocarcinoma cells. *J. Proteome Res.* **8**, 4810–4822
- 44 Senkal, C. E., Ponnusamy, S., Bielawski, J., Hannun, Y. A. and Ogretmen, B. (2010) Antiapoptotic roles of ceramide-synthase-6-generated C<sub>16</sub>-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. *FASEB J.* **24**, 296–308
- 45 Seumois, G., Fillet, M., Gillet, L., Faccinetto, C., Desmet, C., Francois, C., Dewals, B., Oury, C., Vanderplasschen, A., Lekeux, P. and Bureau, F. (2007) *De novo* C<sub>16</sub>- and C<sub>24</sub>-ceramide generation contributes to spontaneous neutrophil apoptosis. *J. Leukocyte Biol.* **81**, 1477–14786
- 46 Pewzner-Jung, Y., Park, H., Laviad, E. L., Silva, L. C., Lahiri, S., Stiban, J., Erez-Roman, R., Brugger, B., Sachsenheimer, T., Wieland, F. et al. (2010) A critical role for ceramide synthase 2 in liver homeostasis: I. alterations in lipid metabolic pathways. *J. Biol. Chem.* **285**, 10902–10910
- 47 Laviad, E. L., Albee, L., Pankova-Kholmyansky, I., Epstein, S., Park, H., Merrill, Jr, A. H. and Futerman, A. H. (2008) Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. *J. Biol. Chem.* **283**, 5677–5684
- 48 Kuksis, A., Myher, J. J., Geher, K., Shaikh, N. A., Breckenridge, W. C., Jones, G. J. and Little, J. A. (1980) Comparative determination of plasma phospholipids by automated gas-liquid chromatographic and manual colorimetric phosphorus methods. *J. Chromatogr.* **182**, 1–26
- 49 Nilsson, A. and Duan, R. D. (2006) Absorption and lipoprotein transport of sphingomyelin. *J. Lipid Res.* **47**, 154–171
- 50 Deevska, G. M. and Nikolova-Karakashian, M. N. (2011) The twists and turns of sphingolipid pathway in glucose regulation. *Biochimie* **93**, 32–38
- 51 Xu, X. X. and Tabas, I. (1991) Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. *J. Biol. Chem.* **266**, 24849–24858
- 52 Liu, J., Zhang, H., Li, Z., Hailemariam, T. K., Chakraborty, M., Jiang, K., Qiu, D., Bui, H. H., Peake, D. A., Kuo, M. S. et al. (2009) Sphingomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice. *Arterioscler. Thromb. Vasc. Biol.* **29**, 850–856

---

Received 4 May 2012/13 June 2012; accepted 19 June 2012

Published as Immediate Publication 19 June 2012, doi 10.1042/BSR20120036

---